Eli Lilly and Company (NYSE:LLY) Shares Acquired by Sugarloaf Wealth Management LLC

Sugarloaf Wealth Management LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 7.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 428 shares of the company’s stock after purchasing an additional 29 shares during the period. Sugarloaf Wealth Management LLC’s holdings in Eli Lilly and Company were worth $249,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. State Street Corp raised its stake in shares of Eli Lilly and Company by 1.9% in the second quarter. State Street Corp now owns 33,878,417 shares of the company’s stock valued at $15,888,300,000 after acquiring an additional 642,274 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Eli Lilly and Company by 2.3% in the second quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock valued at $7,111,568,000 after purchasing an additional 338,077 shares during the period. Morgan Stanley grew its stake in Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Eli Lilly and Company by 3.6% during the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares during the period. Hedge funds and other institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 195,055 shares of company stock valued at $125,254,657 over the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.1 %

NYSE:LLY opened at $762.66 on Tuesday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock’s 50 day simple moving average is $711.51 and its 200-day simple moving average is $627.27. Eli Lilly and Company has a 12-month low of $323.26 and a 12-month high of $800.78. The firm has a market cap of $724.65 billion, a P/E ratio of 131.49, a PEG ratio of 1.66 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the company posted $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 12.41 EPS for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Truist Financial raised their target price on Eli Lilly and Company from $650.00 to $850.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Barclays upped their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $689.52.

Get Our Latest Stock Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.